Navigation Links
NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
Date:3/19/2008

SOPHIA ANTIPOLIS, France, March 19 /PRNewswire/ -- NicOx S.A. (Euronext Paris: COX) today announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API). Naproxcinod is NicOx' lead investigational product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents. The aim of this agreement is to secure commercial supplies of an appropriate scale to ensure the successful commercial launch of naproxcinod. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

Michele Garufi, Chairman and CEO of NicOx, declared: "We are very happy to have signed this agreement with Archimica, which is an essential step as we advance naproxcinod towards the market. With Archimica's extensive manufacturing experience and history of producing APIs for the U.S. and other major markets, NicOx is in a strong position to prepare the regulatory submissions and subsequent market launch of naproxcinod. We now have a large capacity producer, which is capable of supporting the high commercial potential of naproxcinod that has been suggested by our market research."

Under the agreement, Archimica will supply naproxcinod API from Archimica's FDA inspected site in Springfield, Missouri, making Archimica a significant component of NicOx' supply chain for naproxcinod. As per the agreement, NicOx envisages the first deliveries of significant quantities of commercial material being made from the fourth quarter of 2009 onwards, following the installation of dedicated equipment required to manufacture naproxcinod API. NicOx evaluated more than ten potential suppliers for the manufacture of naproxcinod API, prior to the signature of this agreement with Archimica, and may conclude agreements with up to two additional suppliers. T
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), today announced ... David Pendarvis to its board of directors. ... F. Buechler, Ph.D., was president, chief scientific officer ... 1994, Dr. Buechler was Biosite,s director of chemistry. ... senior research scientist for the diagnostics research and ...
(Date:12/16/2009)... HSP-A Soy Peptone. HSP A has been found to be ... ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) ... Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), is ... growth rates and yields. HSP-A has been found to be ...
(Date:12/15/2009)... Repligen Corporation (Nasdaq: RGEN ) ... in research funding to support the ongoing development ... Muscular Dystrophy Association (MDA). This grant will ... and GMP manufacture of a drug candidate for ... not only provides important funding for Repligen,s research ...
(Date:12/15/2009)... Del. and CHARLOTTESVILLE, Va., Dec. 15 /PRNewswire-FirstCall/ ... and the University of Virginia (UVa) in ... into a strategic research collaboration to enhance ... artery disease (CAD) with a secondary focus ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The collaborative ...
Breaking Biology Technology:Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3
... March 2 Morphotek(R), Inc., a subsidiary of,Eisai ... has commenced a,multi-centered Phase II study of its ... MORAb-009, plus the chemotherapy drugs,pemetrexed and cisplatinum, as ... The primary objective of the ...
... March 2 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... obtained a new Senior Secured Term Loan and Revolving ... arranger, administrative agent and lender for both the Term ... a delayed draw secured term loan facility of up ...
... California Institute for Regenerative Medicine ("CIRM") completed a two part ... manufacturing facility, R&D lab and corporate headquarters. , ... ... -- Leadership of the California Institute for Regenerative Medicine ("CIRM") ...
Other Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4CIRM Completes Briefing Visit to Stemedica Cell Technologies 2CIRM Completes Briefing Visit to Stemedica Cell Technologies 3
(Date:12/16/2009)... -- DigitalPersona, Inc., a leader in fingerprint ... agreement with IBM to deploy a new ... on IBM SurePOS 500 retail systems. The ... to more easily and quickly identify users ... to the individuals who perform them. ...
(Date:12/16/2009)... Solutions Inc. is pleased to announce it has ... previously operating as IgeaCare Systems Inc. The newly ... new leadership and funding. ,, IgeaCare Solutions Inc. ... of Chief Executive Officer. Under his direction, the ... servicing and support model; fast and accurate delivery ...
(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2New research shows dinosaurs may have been smaller than we thought 9003 1New research shows dinosaurs may have been smaller than we thought 9003 2Environmental cues control reproductive timing and longevity University of Minnesota study shows 9001 1Environmental cues control reproductive timing and longevity University of Minnesota study shows 9001 2Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care 50066 1Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care 50066 2Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care 50066 3Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care 50066 4
... morbidity and mortality worldwide. Several interacting environmental, biochemical, ... While some of the genes involved in the ... to be discovered. During the last few decades, ... linkage and association methods, and with more targeted ...
... new blood test that can give an early diagnosis ... disease could be launched this summer, reports Marina Murphy ... proteomics company, Power3 Medical Products, said it plans to ... diagnostic test for neurodegenerative diseases on the market, in ...
... rapid weight gain believed to afflict many new college students when ... urban legend: a cautionary tale often told but not well substantiated. ... - located in one of the states with the highest prevalence ... only 1.9 pounds during the first semester, with women gaining slightly ...
Other Biology News:Genetic variants of USF1 are associated with the increased risk for cardiovascular disease 2First diagnostic test for Alzheimer's and Parkinson's disease on the horizon 2Fabled 'Freshman 15' pound gain more often only 5, report researchers 2
FEN-1 (B-4)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
KAI 1 (G-2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: